By Professor Monica M. Lahra

Journal articles

Lan PT; Nguyen HT; Golparian D; Thuy Van NT; Maatouk I; Unemo M; Doanh LH; Hoa PQ; Hoa PD; Minh Phuong PT; Trang TM; Dieu Van TT; Nam PT; Ha Vinh NT; Ha Giang QT; Tung VT; Tuan ND; Phan Nguyen TT; Phuong Vu TT; Thanh Nguyen PT; Duong BH; Van Loi Doan E; Thuy Nguyen DT; Le KT; Bui TM; Pham NN; Kieu Nguyen TT; Thanh Phan TT; Quynh Dang AD; Khoa NT; Lahra M; McDonald R; Kreisel K; Wi T; Schröder D; Jacobsson S, 2024, 'The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) identifies high levels of ceftriaxone resistance across Vietnam, 2023', The Lancet Regional Health - Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101125

Ouk V; Say HL; Virak M; Deng S; Frankson R; McDonald R; Kersh EN; Wi T; Maatouk I; van Hal S; Lahra MM, 2024, 'World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme, Cambodia, 2023', Emerging infectious diseases, 30, pp. 1493 - 1495, http://dx.doi.org/10.3201/eid3007.240354

Unemo M; Sánchez-Busó L; Golparian D; Jacobsson S; Shimuta K; Lan PT; Eyre DW; Cole M; Maatouk I; Wi T; Lahra MM, 2024, 'The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization.', J Antimicrob Chemother, http://dx.doi.org/10.1093/jac/dkae176

Sotheran E; Lane CR; Horan K; Stevens K; Guglielmino C; Bradbury S; Kennedy K; Cooley L; McEwan B; Kahler CM; Mowlaboccus S; Speers DJ; Baird R; Freeman K; Leong L; Warner M; Williamson DA; McVernon J; Lahra M; Jennison AV; Howden BP; Andersson P, 2024, 'Genomic Surveillance of Invasive Meningococcal Disease During a National MenW Outbreak in Australia, 2017-2018', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae249

Lahra MM; van Hal S; Hogan TR, 2024, 'Australian Gonococcal Surveillance Programme, 1 October to 31 December 2023', Communicable diseases intelligence (2018), 48

Lahra MM; Krishnan PS; Hogan TR, 2024, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2023', Communicable diseases intelligence (2018), 48

Lahra MM; Krishnan PS, 2024, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2023', Communicable Diseases Intelligence, http://dx.doi.org/10.33321/cdi.2024.48.21

Lahra MM; Hogan TR, 2024, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2023', Communicable diseases intelligence (2018), 48

Lahra MM; Hogan TR, 2024, 'Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2023', Communicable diseases intelligence (2018), 48

Marshall H; Ward J; Wang B; Andraweera P; McMillan M; Flood L; Bell C; Sisnowski J; Krause V; Webby R; Childs E; Gunathilake M; Egoroff N; Leong L; Lawrence A; Baird R; Freeman K; Menouhos D; Whiley DM; Karnon J; Van Hal S; Lahra MM, 2024, 'Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2023-079144

O’grady K; Hong S; Putsathit P; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Levy A; Moore CV; Nimmo G; Prendergast L; Robson J; Speers DJ; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR, 2024, 'Defining the phylogenetics and resistome of the major Clostridioides difficile ribotypes circulating in Australia', Microbial Genomics, 10, http://dx.doi.org/10.1099/mgen.0.001232

Seib KL; Donovan B; Thng C; Lewis DA; McNulty A; Fairley CK; Yeung B; Jin F; Fraser D; Bavinton BR; Law M; Chen MY; Chow EPF; Whiley DM; Mackie B; Jennings MP; Jennison AV; Lahra MM; Grulich AE, 2024, 'Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2023-081675

Lahra MM; Latham NH; Templeton DJ; Read P; Carmody C; Ryder N; Ellis SE; Madden EF; Parasuraman A; Wells J; Sheppeard V; Armstrong BH; Holland J; Pendle S; Sherry N; Leong L; Papanicolas L; Selvey CE; Van Hal SJ, 2024, 'Investigation and response to an outbreak of Neisseria meningitidis serogroup Y ST-1466 urogenital infections, Australia', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.20

Ouk V; Heng LS; Virak M; Deng S; Lahra MM; Frankson R; Kreisel K; McDonald R; Escher M; Unemo M; Wi T; Maatouk I; Mom PK; Fensham V; Kersh E; Cavailler P; Mundade Y; van Hal SJ; Kundu RL; Hogan TR; Whiley DM; Izumi K; Nishijima T, 2024, 'High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022-23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)', JAC-Antimicrobial Resistance, 6, http://dx.doi.org/10.1093/jacamr/dlae053

O'Brien A; Hart J; Higgins A; Arthur I; Lee GH; Leung M; Kennedy K; Bradbury S; Foster S; Warren S; Korman TM; Abbott IJ; Heney C; Bletchley C; Warner M; Wells N; Wilson D; Varadhan H; Stevens R; Lahra M; Newton P; Maley M; van Hal S; Ingram PR, 2024, 'Nocardia species distribution and antimicrobial susceptibility within Australia', Internal Medicine Journal, 54, pp. 613 - 619, http://dx.doi.org/10.1111/imj.16234

Lahra MM; Van Hal S; Hogan TR, 2024, 'Australian Gonococcal Surveillance Programme, 1 April to 30 June 2023', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.13

Lahra MM; Van Hal S; Hogan TR, 2024, 'Australian Gonococcal Surveillance Programme, 1 January to 31 March 2023', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.12

Lahra MM; Van Hal S; Hogan TR, 2024, 'Australian Gonococcal Surveillance Programme, 1 July to 30 September 2023', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.14

Lahra MM; Hogan TR, 2023, 'Meningococcal Surveillance Australia - Reporting period 1 January to 31 March 2023', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.59

Van Hal SJ; Whiley DM; Le T; Ray S; Kundu RL; Kerr E; Lahra MM, 2023, 'Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype', Journal of Antimicrobial Chemotherapy, 78, pp. 2203 - 2208, http://dx.doi.org/10.1093/jac/dkad221

Ouk V; Pham CD; Wi T; van Hal SJ; Lahra MM, 2023, 'The Enhanced Gonococcal Surveillance Programme, Cambodia', The Lancet Infectious Diseases, 23, pp. e332 - e333, http://dx.doi.org/10.1016/S1473-3099(23)00479-6

Lahra MM; Van Hal S; Hogan TR, 2023, 'Australian Gonococcal Surveillance Programme Annual Report, 2022', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.45

Lahra MM; George CR; Van Hal S; Hogan TR, 2023, 'Australian Meningococcal Surveillance Programme Annual Report, 2022', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.44

George CRR; Lahra MM; Nguyen T; Gatus B, 2023, 'Disc Test for Detecting Staphylococcus aureus Strains Producing Type A and Type C b-Lactamases', Microbiology Spectrum, 11, http://dx.doi.org/10.1128/spectrum.00220-23

Whiley DM; Tickner JA; Kundu RL; Hogan TR; van Hal SJ; Lahra MM, 2023, 'Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis', The Lancet Infectious Diseases, 23, pp. e268 - e269, http://dx.doi.org/10.1016/S1473-3099(23)00359-6

Bell SFE; Ware RS; Lewis DA; Lahra MM; Whiley DM, 2023, 'Antimicrobial susceptibility assays for Neisseria gonorrhoeae: a proof-of-principle population-based retrospective analysis', The Lancet Microbe, 4, pp. e544 - e551, http://dx.doi.org/10.1016/S2666-5247(23)00071-X

Lahra MM; Hurley S; Ray S; Hogan TR, 2023, 'Australian Gonococcal Surveillance Programme, 1 April to 30 June 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.28

Lahra MM; Hurley SM; Ray S; Hogan TR, 2023, 'Australian Gonococcal Surveillance Programme, 1 July to 30 September 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.29

Lahra MM; Hurley SM; Van Hal S; Hogan TR, 2023, 'Australian Gonococcal Surveillance Programme, 1 October to 31 December 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.30

Lahra MM; Hurley SM; Hogan TR, 2023, 'Meningococcal Surveillance Australia Reporting period 1 October to 31 December 2022.', Commun Dis Intell (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.23

Lahra MM; Ray S; Hogan TR, 2023, 'Meningococcal Surveillance Australia Reporting period 1 July to 30 September 2022', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.4

Lahra MM; Ray S; Hogan TR, 2022, 'Meningococcal Surveillance Australia Reporting period 1 April to 30 June 2022', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.81

Ayfan AKS; Macdonald J; Irwin AD; Zowawi HM; Forde BM; Paterson DL; Lahra MM; Whiley DM, 2022, 'Proof-of-concept, rapid, instrument-free molecular detection of Neisseria gonorrhoeae and ciprofloxacin susceptibility', Journal of Antimicrobial Chemotherapy, 77, pp. 2933 - 2936, http://dx.doi.org/10.1093/jac/dkac242

Tickner JA; Lahra MM; Whiley DM, 2022, 'The need for a commercial test using the penA60 allele to identify ceftriaxone-resistant Neisseria gonorrhoeae', The Lancet Infectious Diseases, 22, pp. 1271 - 1272, http://dx.doi.org/10.1016/S1473-3099(22)00520-5

Lahra MM; Hogan TR; Armstrong BH, 2022, 'Australian Gonococcal Surveillance Programme Annual Report, 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.52

Lahra MM; Ray S; Hogan TR, 2022, 'Australian Gonococcal Surveillance Programme, 1 January to 31 March 2022', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.56

Lahra MM; Shoushtari M; Hogan TR, 2022, 'Australian Gonococcal Surveillance Programme, 1 October to 31 December 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.43

Lahra MM; George CR; Hogan TR, 2022, 'Australian Meningococcal Surveillance Programme Annual Report, 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.46

Lahra MM; Ray S; Hogan TR, 2022, 'Meningococcal Surveillance Australia Reporting period 1 January to 31 March 2022', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.36

George CR; Booy R; Nissen MD; Lahra MM, 2022, 'The decline of invasive meningococcal disease and influenza in the time of COVID-19: the silver linings of the pandemic playbook', Medical Journal of Australia, 216, pp. 504 - 507, http://dx.doi.org/10.5694/mja2.51463

Lahra MM; Shoushtari M; Hogan TR, 2022, 'Meningococcal Surveillance Australia Reporting period 1 October to 31 December 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.21

Hui BB; Padeniya TN; Rebuli N; Gray RT; Wood JG; Donovan B; Duan Q; Guy R; Hocking JS; Lahra MM; Lewis DA; Whiley DM; Regan DG; Seib KL, 2022, 'A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection among Urban Men Who Have Sex with Men', Journal of Infectious Diseases, 225, pp. 983 - 993, http://dx.doi.org/10.1093/infdis/jiab581

Lahra MM; Shoushtari M; Hogan TR, 2022, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2021', Communicable diseases intelligence (2018), 46, http://dx.doi.org/10.33321/cdi.2022.46.1

Cabrera-Aguas M; Khoo P; George CRR; Lahra MM; Watson SL, 2022, 'Predisposing factors, microbiological features and outcomes of patients with clinical presumed concomitant microbial and herpes simplex keratitis', Eye (Basingstoke), 36, pp. 86 - 94, http://dx.doi.org/10.1038/s41433-021-01440-1

Lahra MM; Shoushtari M; Hogan TR, 2021, 'Australian Gonococcal Surveillance Programme 1 April to 30 June 2021', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.68

Lahra MM; Shoushtari M; Hogan T, 2021, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2021', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.63

Duan Q; Carmody C; Donovan B; Guy RJ; Hui BB; Kaldor JM; Lahra MM; Law MG; Lewis DA; Maley M; McGregor S; McNulty A; Selvey C; Templeton DJ; Whiley DM; Regan DG; Wood JG, 2021, 'Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia', PLoS Computational Biology, 17, pp. e1009385, http://dx.doi.org/10.1371/journal.pcbi.1009385

Unemo M; Lahra MM; Escher M; Eremin S; Cole MJ; Galarza P; Ndowa F; Martin I; Dillon JAR; Galas M; Ramon-Pardo P; Weinstock H; Wi T, 2021, 'WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study', The Lancet Microbe, 2, pp. e627 - e636, http://dx.doi.org/10.1016/S2666-5247(21)00171-3

Lahra MM; Hogan TR; Shoushtari M; Armstrong BH, 2021, 'Australian Gonococcal Surveillance Programme Annual Report, 2020', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.58

Lahra MM; Shoushtari M; Hogan TR, 2021, 'Australian Gonococcal Surveillance Programme 1 October to 31 December 2020', Communicable diseases intelligence (2018), 45, http://dx.doi.org/10.33321/cdi.2021.45.44

Back to profile page